UPDATE: Structure Therapeutics (GPCR) - The 16.3% Print and the Quiet ATM Upsize

Better data, fatter shelf, and a stock that bled 14% anyway.

The Q1 10-Q dropped this morning alongside an 8-K I want you to read twice. The headline numbers from the ACCESS II 44-week readout are better than the December topline I wrote up — 16.3% placebo-adjusted weight loss at 180 mg (p<0.0001) — and the FDA gave clean end-of-Phase-2 guidance. Phase 3 is now firmly on the calendar for Q3 2026. So why is GPCR down 13.6% to $39.15 over the last ten trading days? Because management quietly removed the cap on the ATM and registered another $150M of ADSs while sitting on a $1.46B war chest. The thesis is intact. The financing optics are not.